Skip to content
Medical Health Aged Care

World Hepatitis Summit 2024 Convenes in Lisbon

World Hepatitis Alliance 3 mins read

The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment

LONDON, ENGLAND / ACCESSWIRE / April 4, 2024 / The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 - 11 April and will bring together global experts to discuss the latest advances in hepatitis prevention, diagnosis and treatment.

World Hepatitis Summit 2024
World Hepatitis Summit 2024
WHS logo

Policy makers, civil society members, representatives from the private sector, academics and other stakeholders will convene to deliberate and share updates on innovative approaches to increase access to testing, vaccination and treatment services for viral hepatitis. Deliberations will also focus on addressing stigma and discrimination and advocating for funding, with an aim for viral hepatitis elimination by 2030.

At the Summit, the World Hepatitis Alliance (WHA) and The European Centre for Disease Prevention and Control (ECDC) will present findings from a first-of-its-kind report examining levels of stigma and discrimination surrounding people living with hepatitis in Europe. The report finds that half (50%) of those living with hepatitis B and C struggle to tell people about their hepatitis. Around a quarter of people living with hepatitis B and C report they have not told their family (23%) or friends (25%) about their hepatitis.

Eliminating the stigma surrounding hepatitis through the introduction of policies and structural changes has been named as a key factor in hepatitis elimination by the World Health Organization (WHO).

On the opening day of the Summit, WHO will release its 2024 Global Hepatitis Report. It is the first consolidated report on viral hepatitis epidemiology, service coverage and product access, with improved data for action. With information from 187 countries, the report outlines regional perspectives and actionable steps to scale up interventions, emphasising the importance of leveraging lessons from the COVID-19 response. A standalone press release will be issued by WHO on 9 April.

About the World Hepatitis Summit

The World Hepatitis Summit is organised by the World Hepatitis Alliance, with the support of the Ministry of Health of Portugal and co-sponsored by WHO. Its mission is to support countries in meeting the targets needed to eliminate viral hepatitis. It is being held in Lisbon and virtually. More information: http://worldhepatitissummit.org/ and https://www.worldhepatitisalliance.org/.

About Viral Hepatitis

Viral hepatitis is inflammation of the liver caused by a virus. WHO says that the total deaths cause by viral hepatitis, including acute cases, cirrhosis and liver cancer, accounted for 1.1 million deaths globally in 2019. In total, over 350 million people in the world are living with viral hepatitis. Each year, over a million people lose their lives because of conditions related to acute hepatitis and chronic infection that cause liver cancer and cirrhosis.

Contact Information

James Gillies
Communications Contact
[email protected]
00447932328287

Steve Shaw
Marketing Manager
[email protected]

SOURCE: World Hepatitis Alliance (WHA)

.

View the original press release on newswire.com.

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/12/2025
  • 09:02
UNSW Sydney

UNSW students claim victory in international artificial heart competition

A team of undergraduate engineering students from UNSW Sydney has claimed first place at a prestigious international artificial heart design competition in Vienna. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.